See also:
Cost to Develop New Pharmaceutical Drug Now Exceeds $2.5B (2014) - A new report published by the Tufts Center for the Study of Drug Development (CSDD) pegs the cost of developing a prescription drug that gains market approval at $2.6 billion, a 145% increase, correcting for inflation, over the estimate the center made in 2003. --
http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18,_2014..pdf
Examining high prescription drug spending for people with employer sponsored health insurance (2016) - "
Prescription drug spending has grown rapidly in the past couple of years, following years of slow growth. Several studies by the federal government, pharmacy benefit managers, and insurers point to high prices for new “specialty” drugs as driving this recent spike, in addition to price increases for some existing brand name drugs. Prescription drugs are one of the leading contributors to health spending growth, and
insurers frequently cite these higher drug costs as a reason for raising premiums." -- "In 2014, 24% of out-of-pocket prescription drug expenses were paid through deductibles, compared to just 4% in 2004. Similarly, 20% of out-of-pocket drug expenses were paid through coinsurance spending in 2014, compared to just 3% in 2004."
THEN we pile on the regulations and chronic underpayment for drugs (do note my post in 489 discussing that pharma was gambling on a big risk based on getting more prescriptions out there to make ACA work) -
http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=21859 (2016)
"6
SUMMARY
Medicare Pharmaceutical and Technology Ombudsman
The Act
establishes a “pharmaceutical and technolog
y ombudsman” within CMS to handle
complaints, grievances, and other requests from pharmaceutical and medical device
manufacturers seeking Medicare coverage for their products. The ombudsman would specifically
be charged with addressing coverage, coding and
payment, providing manufacturers with a
potential new avenue to work with the agency to resolve access barriers arising from these
issues.
The new ombudsman must be in place no later than 12 months after the date of enactment
of the Act.
AMCP will careful
ly monitor regulatory activity in this area, particularly issues
related to the responsibilities of this position.
Reducing Overpayments of Infusion Drugs
Section 5004 addresses findings from an HHS Office of Inspector General (
OIG) report
that
determined Medicare has overpaid for certain drugs and underpaid for others by applying a new
pricing methodology to better reflect actual transaction prices. The payment am
ount for Part B
infusion drugs furnished through durable medical equipment will be set to Average Sales Price
(ASP) plus 6% beginning on January 1, 2017. These drugs were previously paid based on 95%
of the Average Wholesale Price (AWP) that took effect on
October 1, 2003. The OIG concluded
that
applying the ASP+6 percent methodology to infused drugs would result in payment amounts
that reflect actual transaction prices.
AND NOW for the final nail in the coffin of the pharma companies that were so nice to take such a risk on behalf of the ******* greedy selfish ******* Americans
Now both Trump and Clinton intend to import generic's to lower the cost to the people - meanwhile cutting the head off pharma - and truthfully the world, because the US is what drives a lot of the new medications research and development. Nice payback folks - not that anyone cares, because ******* pharma raised the prices 208% - no excuses for the massive increases in the cost of researching and developing them, no excuse for the ******* 50% discounts our government /forces/ them to give anyone over 65, no excuses for our government underpaying them by as much as 6% for over a decade, nooo never mind /all/ of that, it's just greedy pharma...
******* socialist dogs.